Overview
Cortexin is a low-molecular-weight polypeptide preparation (peptides <10 kDa) isolated from the cerebral cortex of young cattle or pigs. Developed in Russia in the 1980s by the Military Medical Academy in St. Petersburg, it is marketed by Geropharm and is one of the most widely prescribed neuroprotective drugs in Russia and several CIS countries. It is not approved in the United States or European Union.
Clinical use of Cortexin spans ischemic stroke, traumatic brain injury, encephalopathies of various origins, epilepsy as an adjunct, cerebral palsy, perinatal CNS damage, and cognitive impairment. The peptide complex is hypothesized to provide trophic support to cortical neurons, modulate excitatory–inhibitory balance, and exert antioxidant effects.
Most clinical evidence comes from Russian-language journals and is methodologically limited (open-label, small sample sizes, heterogeneous outcomes). Western evidence is sparse. Despite this, Cortexin remains a high-volume product within its approved markets.
Quick facts
- Mechanism
- Bovine/porcine cortex–derived polypeptide complex with neurotrophic and neuromodulatory activity
- Primary use
- Stroke, traumatic brain injury, encephalopathy, pediatric CNS conditions (Russia/CIS)
- Evidence
- limited
- FDA
- Not approved
- Route
- Intramuscular injection (10 mg/day adult; 0.5 mg/kg pediatric)
- Typical results
- Reported improvements in post-stroke cognition, pediatric developmental delay, and TBI recovery in Russian trials
Chemical information
Cortexin (Peptide mixture) is a cognition compound with a molecular weight of ~1,000–10,000 g/mol. Its structural characteristics underpin its biological activity in cognitive function and neural health.
How Cortexin works
Cortexin contains a mixture of low-molecular-weight peptides, free amino acids, vitamins, and minerals extracted from cortical tissue. Proposed mechanisms include modulation of GABAergic and glutamatergic neurotransmission (reducing excitotoxicity), upregulation of endogenous neurotrophic factors (BDNF, NGF), inhibition of lipid peroxidation, and stimulation of metabolic activity in cortical neurons.
Animal studies suggest Cortexin reduces infarct volume in ischemic stroke models, decreases neuronal apoptosis, and improves behavioral recovery. Peptide fractions of the preparation have been shown to influence BDNF and NGF expression in cortical cultures, although the active components have not been fully characterized.
Clinical experience reports improvements in attention, memory, language, and overall functional scores when added to standard post-stroke care. In pediatric neurology, it has been used in delayed psycho-speech development, cerebral palsy, and perinatal hypoxic-ischemic encephalopathy.
Limitations include heterogeneity of the source material, lack of standardized active ingredient identity, and absence of large randomized controlled trials meeting Western regulatory standards.
- Neurotrophic support: Modulates BDNF/NGF expression in cortical neurons
- Excitatory–inhibitory balance: Modulates GABA/glutamate neurotransmission
- Antioxidant: Reduces lipid peroxidation in animal stroke models
- Anti-apoptotic: Reduces neuronal death after ischemia in preclinical work
- Pediatric neuroprotection: Most widely used in perinatal and developmental indications
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Composition | Polypeptide complex <10 kDa from cortical tissue | Heterogeneous active ingredient |
| Standard dose | 10 mg IM once daily for 10 days (adults) | Approved Russian dosing regimen |
| Pediatric dose | 0.5 mg/kg (<20 kg) or 10 mg (>20 kg) IM daily for 10 days | Per Russian label |
| Half-life | Not formally characterized | Individual peptide components vary |
| Metabolism | Proteolytic degradation; renal clearance of fragments | No CYP involvement expected |
Dosing & administration
Cortexin dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for Cortexin is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Injection-site pain or induration
- • Mild hypersensitivity reactions
- • Headache
- • Transient agitation in pediatric patients
- • Sleep disturbance if dosed late in the day
Serious / potential risks
- • Allergic reactions to bovine/porcine protein (rare anaphylaxis)
- • Theoretical risk of prion or viral contamination (mitigated by validated sourcing)
- • Unknown long-term effects of repeated courses
- • Quality variability in non-Geropharm sources
- • Use during pregnancy and lactation is not recommended
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Anticonvulsants | Used as adjunct in epilepsy in Russian practice; no formal interaction data | Monitor seizure control |
| CNS stimulants and nootropics | Often combined; no clinical interaction data | Coordinate with prescriber |
| Anticoagulants | No known interaction | Standard monitoring |
| Antipsychotics and antidepressants | No known interaction | Used adjunctively in some protocols |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Cortexin is a cognition compound with research interest in neuroprotection, cognition, brain injury. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying cognitive function and neural health
- • Individuals interested in neuroprotection under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Skoromets AA, Stakhovskaya LV, Belkin AA, et al.. New possibilities of neuroprotection in the treatment of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova (2008). PMID: 19238075
- [2] Gusev EI, Skvortsova VI.. Neuroprotective therapy in ischemic stroke. Cortexin's place. Zh Nevrol Psikhiatr Im S S Korsakova (2007). PMID: 18379471
- [3] Granstrem OK, Sorokina EG, Storozhevykh TP, et al.. Cortexin and its effects in models of glutamate excitotoxicity. Bull Exp Biol Med (2010). doi: 10.1007/s10517-010-0888-1 PMID: 20672398